Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01221
|
|||||
| Drug Name |
Rosiglitazone
|
|||||
| Indication | Type 2 diabetes [ICD11: 5A11] | Approved | [1] | |||
| Formula |
C18H19N3O3S
|
|||||
| Canonical SMILES |
CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
|
|||||
| InChI |
InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
|
|||||
| InChIKey |
YASAKCUCGLMORW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 122320-73-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 357.4 | Topological Polar Surface Area | 96.8 | ||
| Heavy Atom Count | 25 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
3.1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:50122
|
|||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Rosiglitazone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.